Portal de Periódicos da CAPES

Serum soluble interleukin‐2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B‐cell lymphoma

2009; Wiley; Volume: 100; Issue: 7 Linguagem: Inglês

10.1111/j.1349-7006.2009.01167.x

1349-7006

Toshiaki Morito, Megumu Fujihara, Hideki Asaoku, Akira Tari, Yasuharu Sato, Kouichi Ichimura, Takehiro Tanaka, Katsuyoshi Takata, Maiko Tamura, Tadashi Yoshino,

CAR-T cell therapy research

Diffuse large B‐cell lymphoma is the most common form of non‐Hodgkin lymphoma. Although many studies have attempted to identify prognostic factors, most have focused on conventionally treated patients. The influence of anti‐CD20 antibody (rituximab) should be considered now. We evaluated the prognostic significance of serum soluble interleukin‐2 receptor levels and germinal center B‐cell‐like or non‐germinal center B‐cell like subgroups in 80 patients with diffuse large B‐cell lymphoma, who had been treated with rituximab. Serum soluble interleukin‐2 receptor levels ranged from 322 to 39900 U/mL (median 1365 U/mL). Sixteen (20%) were germinal center B‐cell‐like subgroups, and the remainder (80%) non‐germinal center B‐cell‐like. Survival analysis associated lower serum soluble interleukin‐2 receptor level and germinal center B‐cell‐like phenotype with better overall survival ( P = 0.015), whereas multivariate analysis, including International Prognostic Index factors, revealed that only higher performance status score and higher serum lactate dehydrogenase levels significantly affected survival. However, serum soluble interleukin‐2 receptor levels were elevated in patients with higher International Prognostic Index scores as well as in the non‐germinal center B‐cell‐like subgroup. Serum soluble interleukin‐2 receptor levels, International Prognostic Index, and subphenotypes were strongly correlated with each other. Our study showed that soluble interleukin‐2 receptor is quite useful and may serve as a substitute for the International Prognostic Index, especially for patients undergoing treatment. Moreover, the differentiation between the germinal center B‐cell‐like and non‐germinal center B‐cell‐like phenotypes is also useful for predicting patients with diffuse large B‐cell lymphoma, even among those treated with rituximab. ( Cancer Sci 2009; 100: 1255–1260)